Better Therapeutics Appoints Major General Elder Granger, MD, US Army (Ret’d) to Board of Directors
November 11, 2021
Better Therapeutics, Inc. (“Better Therapeutics”; NASDAQ: BTTX), a digital prescription therapy company that develops cognitive behavioral therapy to address the root causes of cardiometabolic disease, today announced the appointment of Major – General Elder Granger, MD, US Army (retired) to its board of directors.
“Dr. Granger’s leadership history in navigating complex political, regulatory and competitive environments will be welcome additions to the Better Therapeutics Board of Directors,” said David Perry, Co-Founder and President of Better Therapeutics. “His extensive board experience coupled with an unwavering commitment to improving healthcare delivery will be invaluable as we work to establish our digital prescription therapies as the new standard of care for people with cardiometabolic disease. . ”
Dr Granger joins the Better Therapeutics Board of Directors with decades of experience in acquiring, operating and integrating managed care programs into the military healthcare system. He is currently President and CEO of The 5Ps, a healthcare, education and leadership consulting organization. Prior to retiring from the U.S. Army in 2009, he served as Deputy Director and Program Director of TRICARE Management Business, Office of the Assistant Secretary of Defense (Health Affairs) in Washington, DC, where he was the Senior Advisor to the Under Secretary of Defense (Health Affairs) on the policy and performance of the Ministry of Defense health plan.
“Improving healthcare systems has been a major passion for me throughout my career, and Better Therapeutics is at the forefront of developing innovative solutions that could truly change the future of healthcare”, Dr Granger said. “I look forward to offering my healthcare expertise and helping the team move their digital prescription therapies towards commercialization to reach more of the millions of people in the United States living with diseases. cardiometabolic. ”
“Dr. Granger is a national treasure,” said Kevin Appelbaum, co-founder and CEO. “I am honored by his decision to serve on our Board of Directors and, as a veteran colleague, I look forward to working closely with him to make our solutions accessible to the more than 10 million veterans, from active-duty military personnel and their families, who suffer a disproportionate burden of cardiometabolic disease. ”
Dr Granger is currently independent director and member of the nominating and governance committee of Cerner (NASDAQ: CERN), independent director and chairman of the compliance committee of Cigna (NYSE: CI) and independent director of DLH (NASDAQ: DLHC).
Boardspan Inc. acted as advisor to Better Therapeutics in connection with this appointment.
About Better Therapeutics
Better Therapeutics is a digital prescription therapy (PDT) company developing a new form of cognitive behavioral therapy to address the root causes of cardiometabolic disease. The company has developed a proprietary platform for the development of FDA-regulated software solutions for type 2 diabetes, heart disease, and other conditions. The cognitive behavioral therapy provided by Better Therapeutics’ PDT is designed to enable changes in neural pathways in the brain so that lasting behavior changes become possible. Tackling the underlying causes of these diseases has the potential to dramatically improve patient health while reducing healthcare costs. Better Therapeutics’ clinically validated mobile apps are intended to be prescribed by physicians and reimbursed like traditional medicines. For more information visit: bettertx.com
Heidi Chokeir, Ph.D.
+1 619 203 5391